DekaBank Deutsche Girozentrale’s AbCellera Biologics ABCL Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-87,000	Closed	-$425K	–	1099
2025 Q4	$425K	Hold	87,000	–	–	﹤0.01%	1033
2025 Q3	$412K	Hold	87,000	–	–	﹤0.01%	1023
2025 Q2	$306K	Hold	87,000	–	–	﹤0.01%	1061
2025 Q1	$198K	Hold	87,000	–	–	﹤0.01%	1113
2024 Q4	$255K	Hold	87,000	–	–	﹤0.01%	1111
2024 Q3	$224K	Hold	87,000	–	–	﹤0.01%	1145
2024 Q2	$249K	Hold	87,000	–	–	﹤0.01%	1124
2024 Q1	$389K	Hold	87,000	–	–	﹤0.01%	1051
2023 Q4	$511K	Hold	87,000	–	–	﹤0.01%	1034
2023 Q3	$403K	Hold	87,000	–	–	﹤0.01%	1066
2023 Q2	$571K	Hold	87,000	–	–	﹤0.01%	1001
2023 Q1	$642K	Hold	87,000	–	–	﹤0.01%	965
2022 Q4	$867K	Hold	87,000	–	–	﹤0.01%	916
2022 Q3	$850K	Hold	87,000	–	–	﹤0.01%	912
2022 Q2	$865K	Sell	87,000 -100,000	-53%	-$847K	﹤0.01%	905
2022 Q1	$1.82M	Sell	187,000 -8,000	-4%	-$75.7K	﹤0.01%	778
2021 Q4	$2.65M	Buy	+195,000	New	+$2.96M	0.01%	712

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ABCL Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 87,000 shares — an estimated $425K sold.

DekaBank Deutsche Girozentrale first reported a position in ABCL in Q4 2021 and held it in 17 quarters. The position peaked at $2.65M in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 87,000 AbCellera Biologics shares in Q1 2026, an estimated $425K.
DekaBank Deutsche Girozentrale first reported a position in AbCellera Biologics in Q4 2021 and held it in 17 quarters.
DekaBank Deutsche Girozentrale's AbCellera Biologics position peaked at $2.65M in Q4 2021.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.